cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Atara Biotherapeutics Inc
2 own
9 watching
Current Price
$5.46
$0.33
(6.43%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
518.04M
52-Week High
52-Week High
16.07
52-Week Low
52-Week Low
2.83
Average Volume
Average Volume
0.91M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization518.04M
icon52-Week High16.07
icon52-Week Low2.83
iconAverage Volume0.91M
iconDividend Yield--
iconP/E Ratio--
What does the Atara Biotherapeutics Inc do?
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More
How much money does Atara Biotherapeutics Inc make?
News & Events about Atara Biotherapeutics Inc.
Business Wire
1month ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences. Since 2020, I have had the privilege...
Business Wire
1month ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated interim analysis and safety results...
Business Wire
2 months ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief...
Benzinga
2 months ago
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.78. read more...
Business Wire
3 months ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new magnetic resonance imaging (MRI) biomarker...
Frequently Asked Questions
Frequently Asked Questions
What is Atara Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Atara Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Atara Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Atara Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Atara Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Atara Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Atara Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Atara Biotherapeutics Inc?
plus_minus_icon
What percentage is Atara Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Atara Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.46
$0.33
(6.43%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00